#United States #VETMEDIN #Boehringer Ingelheim #dog health #Duluth

Boehringer Ingelheim Launches VETMEDIN® Solution

In a dramatic advancement for pet health, Boehringer Ingelheim, a frontrunner in animal healthcare, has introduced VETMEDIN® Solution (pimobendan oral solution). This product marks a groundbreaking achievement as the first oral solution authorized by the U.S. Food and Drug Administration (FDA) aimed at treating congestive heart failure (CHF) in dogs, particularly those suffering from myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM).

Heart disease, much like in humans, is alarmingly common among dogs, impacting around 10% of them during their lifetime. Among these conditions, MMVD and DCM are prevalent, often leading to CHF, where the heart struggles to pump blood effectively, jeopardizing the dog’s overall health. VETMEDIN has been globally recognized as a leading medication in canine cardiology, and with this new solution, pet owners are provided with a convenient, liquid option for administering treatment, particularly beneficial for small dogs or those with difficulties swallowing tablets.

Daniel Watkins, Vice President of US Pet Business at Boehringer Ingelheim, highlighted the company's commitment to innovation stating, "We continue to deliver new innovations rooted in robust clinical evidence to help more pets. We know some dogs and pet owners may prefer a liquid medication, especially for smaller dogs. With VETMEDIN® Solution, an easy-to-use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives."

The VETMEDIN® Solution serves the same dual mode of action as its chewable tablet counterpart. Registered as a flavorless solution, it's recommended for administration directly into the dog’s mouth twice a day. By providing this easy-to-swallow option, Boehringer Ingelheim aims to improve both the longevity and quality of life for canines suffering from these life-threatening conditions.

This new oral solution retains the same effectiveness as the conventional VETMEDIN tablets, which have already contributed to millions of additional years of life for dogs worldwide since their introduction 25 years ago. The chewable tablets are utilized for dogs exhibiting signs of mild to severe CHF due to clinical MMVD or DCM. They can also be combined safely with other therapies, depending on the individual case.

In addition to VETMEDIN® Solution, Boehringer Ingelheim offers VETMEDIN®-CA1, which possesses FDA conditional approval for preclinical MMVD in dogs, potentially delaying the occurrence of heart failure symptoms.

As with any medication, it’s imperative for pet owners to be aware of the safety information associated with VETMEDIN. Both the solution and chewable tablets are strictly for use in dogs showing clinical indications of heart failure and should not be administered to dogs with conditions like hypertrophic cardiomyopathy or aortic stenosis. Common side effects noted in field studies include lethargy, diarrhea, and reduced appetite among others, making it critical for owners to consult with a veterinarian before starting treatment.

Boehringer Ingelheim emphasizes that the health connection between humans and animals is crucial, leading to their ongoing dedication towards creating innovative healthcare solutions. Their extensive research and development efforts underscore a sustainable future not just for pets but for all of society.

For more detailed information about VETMEDIN® and other offerings in animal health, visit the company’s official website at Boehringer Ingelheim Animal Health. This new VETMEDIN® Solution is a promising tool in the fight against dog heart diseases, aiming for a healthier, longer-lasting life for our beloved pets.